Approximation of bicarbonate concentration using serum total carbon dioxide concentration in patients with non-dialysis chronic kidney disease

Impact of decreased levels of total CO2 on in-hospital mortality in patients with COVID-19

Decreased total CO2 (tCO2) is significantly associated with all-cause mortality in critically ill patients. Because of a lack of data to evaluate the impact of tCO2 in patients with COVID-19, we assessed the impact of tCO2 on all-cause mortality in this study. We retrospectively reviewed the data of hospitalized patients with COVID-19 in two Korean referral hospitals between February 2020 and September 2021. The primary outcome was in-hospital mortality. We assessed the impact of tCO2 as a continuous variable on mortality using the Cox-proportional hazard model. In addition, we evaluated the relative factors associated with tCO2 ≤ 22 mmol/L using logistic regression analysis. In 4,423 patients included, the mean tCO2 was 24.8 ± 3.0 mmol/L, and 17.9% of patients with tCO2 ≤ 22 mmol/L. An increase in mmol/L of tCO2 decreased the risk of all-cause mortality by 4.8% after adjustment for age, sex, comorbidities, and laboratory values. Based on 22 mmol/L of tCO2, the risk of mortality was 1.7 times higher than that in patients with lower tCO2. This result was maintained in the analysis using a cutoff value of tCO2 24 mmol/L. Higher white blood cell count; lower hemoglobin, serum calcium, and eGFR; and higher uric acid, and aspartate aminotransferase were significantly associated with a tCO2 value ≤ 22 mmol/L. Decreased tCO2 significantly increased the risk of all-cause mortality in patients with COVID-19. Monitoring of tCO2 could be a good indicator to predict prognosis and it needs to be appropriately managed in patients with specific conditions.

Real-world evidence for steroidal mineralocorticoid receptor antagonists in patients with chronic kidney disease

Background

Mineralocorticoid receptor antagonists (MRAs) were shown to delay chronic kidney disease (CKD) progression in patients with hypertension and/or heart failure (HF) and proteinuria.

Objective

We conducted a systematic literature review on real-world evidence to identify the literature gaps related to the efficacy and safety outcomes of MRAs administered to CKD patients.

Results

A total of 751 records were identified of which, 23 studies (26 publications) were analyzed. Studies included heterogeneous populations, including the overall CKD, CKD and diabetes, CKD and HF, and CKD and a history of cardiovascular disease. Most of the studies were small and non-rigorous, resulting in a notable lack of evidence in these populations. In the overall CKD population, steroidal MRAs resulted in a significant or sustained eGFR reduction but no efficacy in delaying progression to end-stage kidney disease. No cardiovascular protection was found. Results for all-cause mortality and hospitalization for HF were inconsistent; however, the longest follow-up studies indicate similar or lower incidence for spironolactone non-users. Most results consistently reported a higher incidence of hyperkalemia among patients on steroidal MRAs in all CKD stages, and side effects led to high discontinuation rates in the real-world setting.

Conclusions

Despite the limited availability of evidence on the effectiveness and safety of steroidal MRAs in CKD patients and subgroups with diabetes, HF or history of cardiovascular disease, MRAs were shown to have a limited effect on renal and cardiovascular outcomes. Gaps in the evidence regarding the efficacy and safety of MRAs are particularly relevant in diabetic CKD patients; therefore, further research is warranted.

The mTORC1-SLC4A7 axis stimulates bicarbonate import to enhance de novo nucleotide synthesis

Bicarbonate (HCO3-) ions maintain pH homeostasis in eukaryotic cells and serve as a carbonyl donor to support cellular metabolism. However, whether the abundance of HCO3- is regulated or harnessed to promote cell growth is unknown. The mechanistic target of rapamycin complex 1 (mTORC1) adjusts cellular metabolism to support biomass production and cell growth. We find that mTORC1 stimulates the intracellular transport of HCO3- to promote nucleotide synthesis through the selective translational regulation of the sodium bicarbonate cotransporter SLC4A7. Downstream of mTORC1, SLC4A7 mRNA translation required the S6K-dependent phosphorylation of the translation factor eIF4B. In mTORC1-driven cells, loss of SLC4A7 resulted in reduced cell and tumor growth and decreased flux through de novo purine and pyrimidine synthesis in human cells and tumors without altering the intracellular pH. Thus, mTORC1 signaling, through the control of SLC4A7 expression, harnesses environmental bicarbonate to promote anabolic metabolism, cell biomass, and growth.

How important is dietary management in chronic kidney disease progression? A role for low protein diets

High dietary protein intake may lead to increased intraglomerular pressure and glomerular hyperfiltration, which in the long-term can lead to de novo or aggravating preexisting chronic kidney disease (CKD). Hence, a low protein diet (LPD, 0.6 to 0.8 g/kg/day) is recommended for the management of CKD. There are evidences that dietary protein restriction mitigate progression of CKD and retard the initiation of dialysis or facilitate incremental dialysis. LPD is also helpful to control metabolic derangements in CKD such as metabolic acidosis and hyperphosphatemia. Recently, a growing body of evidence has emerged on the benefits of plant-dominant low-protein diet (PLADO), which composed of > 50% plant-based sources. PLADO is considered to be helpful for relieving uremic burden and metabolic complications in CKD compared to animal protein dominant consumption. It may also lead to favorable alterations in the gut microbiome, which can modulate uremic toxin generation along with reducing cardiovascular risk. Alleviation of constipation in PLADO may minimize the risk of hyperkalemia. A balanced and individualized dietary approach for good adherence to LPD utilizing various plant-based sources as patients' preference should be elaborated for the optimal care in CKD. Periodic nutritional assessment under supervision of trained dietitians should be warranted to avoid protein-energy wasting.

Relationship Between Serum Total Carbon Dioxide Concentration and Bicarbonate Concentration in Patients Undergoing Peritoneal Dialysis

Background

Few studies have assessed the relationship between serum total carbon dioxide (CO₂) and bicarbonate ion (HCO₃⁻) concentration in patients undergoing peritoneal dialysis. We determined the agreement between serum total CO₂ and HCO₃⁻ concentration and the diagnostic accuracy of serum total CO₂ for the prediction of low (HCO₃⁻ <24 mEq/L) and high (HCO₃⁻ ≥24 mEq/L) bicarbonate concentrations in patients on peritoneal dialysis.

Methods

We collected 245 samples of venous blood from 51 patients on peritoneal dialysis. Independent factors that correlated with the HCO₃⁻ concentration were analyzed using multiple linear regression analysis. The diagnostic accuracy of serum total CO₂ was evaluated by receiver operating characteristic (ROC) curve analysis and a 2×2 table. Agreement between serum total CO₂ and HCO₃⁻ concentration was assessed by Bland-Altman analysis.

Results

Serum total CO₂ was independently correlated with HCO₃⁻ concentration (β = 0.354, p < 0.001). The area under the curve of serum total CO₂ for the identification of low and high bicarbonate concentrations was 0.909. The diagnostic accuracy of serum total CO₂ for the prediction of low and high bicarbonate concentrations was: sensitivity, 91.5%; specificity, 74.7%; positive predictive value, 53.5%; negative predictive value, 96.5%; and accuracy, 78.8%. Bland-Altman analysis showed a moderate agreement between serum total CO₂ and HCO₃⁻ concentration.

Conclusion

Serum total CO₂ correlated closely with the HCO₃⁻ concentration in patients undergoing peritoneal dialysis. Serum total CO₂ might be useful for predicting low and high bicarbonate in peritoneal dialysis patients.

Low serum total CO2 and its association with mortality in patients being followed up in the nephrology outpatients clinic

Large-scale studies have not been conducted to assess whether serum hypobicarbonatemia increases the risk for kidney function deterioration and mortality among East-Asians. We aimed to determine the association between serum total CO₂ (TCO₂) concentrations measured at the first outpatient visit and clinical outcomes. In this multicenter cohort study, a total of 42,231 adult nephrology outpatients from 2001 to 2016 were included. End-stage renal disease (ESRD) patients on dialysis within 3 months of the first visit were excluded. Instrumental variable (IV) was used to define regions based on the proportion of patients with serum TCO₂ < 22 mEq/L. The crude mortality rate was 12.2% during a median 77.0-month follow-up period. The Cox-proportional hazard regression model adjusted for initial kidney function, alkali supplementation, and the use of diuretics demonstrated that low TCO₂ concentration was not associated with progression to ESRD, but significantly increased the risk of death. The IV analysis also confirmed a significant association between initial TCO₂ concentration and mortality (HR 0.56; 95% CI 0.49–0.64). This result was consistently significant regardless of the underlying renal function. In conclusion, low TCO₂ levels are significantly associated with mortality but not with progression to ESRD in patients with ambulatory care.

Relationship between serum total carbon dioxide concentration and bicarbonate concentration in patients undergoing hemodialysis

Background

Few studies have investigated the relationship between serum total carbon dioxide (CO₂) concentration and bicarbonate ion (HCO₃^-) concentration in patients undergoing hemodialysis. We determined the agreement and discrepancy between serum total CO₂ and HCO₃^- concentrations and the diagnostic accuracy of serum total CO₂ for the prediction of low (HCO₃^- < 24 mEq/L) and high (HCO₃^- ≥ 24 mEq/L) bicarbonate concentrations in hemodialysis patients.

Methods

One hundred forty-nine arteriovenous blood samples from 84 hemodialysis patients were studied. Multiple linear regression analysis was used to determine factors correlated with HCO₃^- concentration. Diagnostic accuracy of serum total CO₂ was evaluated using receiver operating characteristic curve analysis and a 2 × 2 table. Agreement between serum total CO₂ and HCO₃^- concentrations was assessed using Bland-Altman analysis.

Results

Serum total CO₂ concentration was closely correlated with HCO₃^- concentration (β = 0.858, P < 0.001). Area under the curve of serum total CO₂ for the identification of low and high bicarbonate concentrations was 0.989. Use of serum total CO₂ to predict low and high bicarbonate concentrations had a sensitivity of 100%, specificity of 50.0%, positive predictive value of 96.5%, negative predictive value of 100%, and accuracy of 96.6%. Bland-Altman analysis showed moderate agreement between serum total CO₂ and HCO₃^- concentrations. Discrepancies between HCO₃^- and serum total CO₂ concentrations (serum total CO₂ - HCO₃^- ≤ -1) were observed in 89 samples.

Conclusion

Serum total CO₂ concentration is closely correlated with HCO₃^- concentration in hemodialysis patients. However, there is a non-negligible discrepancy between serum total CO₂ and HCO₃^- concentrations.

Serum total carbon dioxide as a prognostic factor for 28-day mortality in patients with sepsis

OBJECTIVE

Metabolic acidosis is commonly associated with the disease severity in patients with sepsis or septic shock. This study was performed to investigate the association between serum total carbon dioxide (TCO₂₎ concentration and 28-day mortality in patients with sepsis.

METHODS

This study was a multicenter retrospective cohort study of patients with sepsis or septic shock. The relationships between serum TCO₂ and 28-day mortality, bicarbonate, pH, lactate, and anion gap were determined with cubic spline curves. The patients were divided into four groups according to their serum TCO₂ concentration: Group I (TCO₂ > 20 mmol/l), Group II (15 < TCO₂ ≤ 20 mg/dl), Group III (10 < TCO₂ ≤ 15 mmol/l), and Group IV (TCO₂ ≤ 10 mmol/l).

RESULTS

A total of 3168 patients were included in the analysis, and the overall mortality rate was 24.1%. Serum TCO₂ concentrations below 20 mmol/l showed an almost linear correlation with mortality as well as with lactate, bicarbonate, and pH. The 28-day mortality rates of Group I, II, III, and IV were 18.3%, 23.6%, 32.6%, and 50.0%, respectively (p < .001). In Multivariable Cox proportional hazard regression analysis, the groups with lower serum TCO₂ concentrations had a higher risk of 28-day mortality compared with Group I: Group II (Hazard ratio (HR), 1.35; 95% confidence interval (CI), 1.11-1.64), Group III (HR, 1.74; 95% CI, 1.37-2.21), and Group IV (HR, 2.72; 95% CI, 2.03-3.64).

CONCLUSIONS

Serum TCO₂ concentrations of 20 mmol/l or less were associated with 28-day mortality in patients with sepsis.

Metabolic acidosis is associated with pulse wave velocity in chronic kidney disease: Results from the KNOW-CKD Study

Metabolic acidosis is common in chronic kidney disease (CKD) and may have various deleterious consequences. Arterial stiffness in CKD patients is associated with poor cardiovascular outcomes. The present study aimed to evaluate the association between serum bicarbonate and arterial stiffness using the baseline cross-sectional data set of a large-scale Korean CKD cohort. 2,238 CKD patients were enrolled in the KoreaN Cohort Study for Outcome in Patients With Chronic Kidney Disease (KNOW-CKD) from 2011 to 2016. The present study was conducted on 1,659 patients included in this cohort with baseline serum bicarbonate and brachial-to-ankle pulse wave velocity (baPWV) data. Metabolic acidosis was defined as a serum bicarbonate level of <22 mmol/L, and baPWV was used as a surrogate of arterial stiffness. Mean serum bicarbonate was 25.8 ± 3.6 mmol/L. 210 (12.7%) patients had metabolic acidosis. baPWV was significantly higher in patients with metabolic acidosis (P < 0.001) and showed a significant inverse correlation with serum bicarbonate (Unstandardized β −16.0 cm/sec; 95% CI −20.5, −11.4; P < 0.001) in an unadjusted model, which was retained after adjustment (Unstandardized β −5.4 cm/sec; 95% CI −9.9, −1.0; P = 0.017). Metabolic acidosis was found to be associated with a high baPWV in pre-dialysis CKD patients.